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Measuring Airway Inflammation in
Asthmatic Children
Laura Tenero*, Marco Zaffanello, Michele Piazza and Giorgio Piacentini
Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Verona, Italy
Asthma is the most common chronic respiratory disease in children characterized
by airways inflammation, bronchial hyperresponsiveness, recurrent reversible airways
obstruction, and respiratory symptoms. The diagnosis of the disease is based on clinical
history, airways obstruction at spirometry, and bronchial reversibility. Asthma treatment
is aimed to disease control, through the use of controller treatment and monitoring lung
function. However, lung function and symptoms not always reflect the underlying airways
inflammation and response to the therapy. Objective parameters of asthma inflammation
could be important for the clinician in the management of patients with asthma. In the last
years, some studies were focused on biomarkers to identify phenotype, inflammation,
and pathobiological pathways to help the clinician in the diagnosis and in personalizing
the management. Accordingly, clinically feasible tests are represented by the collection
of exhaled breath condensate (EBC) and measurement of exhaled nitric oxide (FeNO).
Other—methods such as the evaluation of volatile organic compound (VOCs), that reflect
airways inflammation and treatment efficacy, are currently used for research purposes
For some of these methods, The lack of standardization in pre-collection, collection,
post-collection of samples, and interpretation of the results may a problem in clinical
practice. Improved these limitations, several biomarkers will be useful to distinguish
patients with a different disease condition to personalize the treatment.
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INTRODUCTION
Asthma is a chronic respiratory disease characterized by inflammation of the airways, bronchial
hyperresponsiveness, recurrent reversible airway obstruction, and respiratory symptoms (1).
Asthma is the most common chronic respiratory disease in childhood with an incidence between 1
and 18% in people from different countries.
The diagnosis of asthma is based on anamnestic data, clinical evaluation, limitation of the
airflow, and bronchial reactivity (1). The goal of asthma treatment is the control of respiratory
symptoms with controller daily drugs, reduction of rescue medications needed to maintain a
regular daily activity and reaching a normal lung function (1). Though airways inflammation is
a pivotal characteristic of the disease, it is not directly related to lung function test or symptoms (2)
and with the real response to the therapy (3).
Therefore, objective parameters of airway inflammation should be considered relevant for the
treatment choice in asthmatic patients.
The assessment of biomarkers in the exhaled breath of patients with asthma and other lung
diseases is a very attractive approach to monitor airways inflammation. Biomarkers are objectively
measurable indicators of the biological and pathological processes as well as of the pharmacological
responses to the therapeutic intervention (4).
Tenero et al. Biomarkers in Airways Inflammation
An ideal biomarker should be easy to collect and measure,
inexpensive, noninvasive, and feasible in children capable to
contribute to the phenotyping of the disease and to the
assessment of treatment response (4, 5).
In order to have a clinically useful tool, there are
important issues regarding sensibility, reproducibility,
and variability of the methods, that need to be evaluated
before moving from bench to bedside. In the next future,
a number of recently proposed methods are expected
to be clinically useful to predict the progression of the
disease, to the phenotyping and endotyping of the disease
in order to move toward a personalized treatment in asthma
(Figure 1).
Bronchoscopy with bronchoalveolar lavage (BAL) and
endobronchial biopsy are considered the gold standards for
assessing airway inflammation and remodeling in asthma but,
being invasive methods, they have a limited use in the clinical
setting, in particular in pediatric care (2).
In recent years, therefore, researchers have focused their
studies to define surrogate biomarkers to be proposed in
the assessment of airway inflammation in asthmatic children
and are shortly revised in the following sections (4–6)
(Figure 1).
INDUCED SPUTUM
The method of induced sputum is a relatively noninvasive
diagnostic procedure able to harvest cells and mediators from
the lower airway (2) which, however, requires a level of expertise
in the collection in order to obtain adequate samples and
reliable results. Sputum can be induced in children older than 6
years after inhalation of nebulized hypertonic saline solution at
increasing concentration (7, 8).
The procedure to collect sputum is standardized by European
Respiratory Society Task Force and is applicable to children older
than 8 years (9, 10).
However, the practical use of this method is limited due
to technical issues which can make the feasibility at clinical
setting difficult to perform for regular assessment of airways
inflammation in children (11, 12). In particular, hypertonic
saline inhalation may cause bronchoconstriction, especially in
asthmatic children, for whom pre-medication with β2-agonist
may be necessary. Furthermore, the post-collection analysis
needs skilled laboratory personnel for mediator assay and cell
specimens to be transferred onto slides and properly stained.
Trained physicians are also needed in order to have a correct
reading of the results from the specimens.
Several studies demonstrated a strong correlation between
cellular elements of BAL and cells collected from in the airways
through the induced sputum method.
The dominant cell in sputum from normal children is the
macrophages, and the normal ratio for eosinophils in sputum
from children is 2.5% (7).
Different inflammatory patterns are being identified
from sputum of asthmatic children and adults: eosinophilic,
neutrophilic, mixed, and paucigranulocytic types (13).
Sputum eosinophilia is a marker of severity of allergic
inflammation in asthma and is characterized by elevated numbers
of eosinophils, and eosinophil cationic protein concentration, as
well as increased nitric oxide and hydrogen peroxide levels in
exhaled breath. The patients with an eosinophilic pattern are
expected to have a better response to corticosteroids therapy (14).
Also, children with stable asthma show increased number
of eosinophils and bronchial epithelial cells in their sputum
(15, 16). During asthma exacerbation, eosinophils and mast
cells are more represented in the samples obtained from the
airways through the method of induced sputum and eosinophil
cationic protein concentrations are higher in the fluid phase
of the samples. Some patients have sputum neutrophilia with
improved levels of interleukin 8 (17). On the other hand, children
with asymptomatic airway hyperresponsiveness are expected to
have normal cell counts, whereas patients with cystic fibrosis have
sputum neutrophilia (15, 18).
EXHALED BREATH CONDENSATE
Exhaled breath condensate (EBC) is a noninvasive method aimed
to evaluate volatile markers and inflammatory mediators that
may contribute to evaluate asthma pathophysiology.
EBC collects particles from airway lining fluid by the
condensation of warm humid breath onto a cold surface in a
condensing device.
EBC collection, as described in ATS/ERS guidelines, requires
a refrigerated device (19) and patient are requested to breath
at tidal volume for 10–15min. During this time the airways
lining fluid undergoes an aerosolization process and the exhaled
fraction is condensed in a cooling device (0 to−20◦C) (20).
The most frequently evaluated parameters in EBC are pH,
exhaled markers of oxidative stress and inflammation.
EBC is composed of water vapor, unstable volatiles such
as CO2 and H2O2, inorganic (O2, N2), and organic (CO2)
particles, exogenous, and endogenous organic compounds,
protein, and cytokines (21). In the respiratory tract, H2O2
may be released from inflamed cells—including neutrophils,
macrophages, eosinophils, and epithelial cells. Nitrogen redox
forms such as nitrite (NO2 –) and nitrate (NO3 –) are present
in the epithelial lining fluid of the human respiratory tract.
High concentrations of NO2 and NO2+NO3 were showed
in patients with asthma, CF and bronchiectasis compared with
healthy controls (21).
The pH of EBC is a non-specific marker of airway disease
being a median normal pH value of 8.0 in children from 0 to
20 years (22). Some studies showed a lower pH in children with
stable asthma than healthy controls and a lower pH value in
children with severe than mild asthma (23, 24). In addition,
asthmatic patients not adequately treated with ICS have been
demonstrated to have a lower pH than those properly treated.
Patients with acute exacerbation had a higher pH value after the
treatment with budesonide (23, 24).
At present, no association has been reported between
asthma symptoms, lung function, FeNO, and airway
hyperresponsiveness (25, 26).
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FIGURE 1 | Summary of single and multiple biomarkers detection methods to assess airways inflammation in children.
Biomarkers related to oxidative stress like H2O2, 8-
isoprostane, asymmetric dimethylarginine (ADMA), aldehydes,
and nitrite/nitrate are important to be evaluated in EBC in a
number of airway diseases, including asthma.
Asymmetric dimethylarginine (ADMA) is an EBC marker
of oxidative stress which can be assessed by the UPLC-MS/MS
technique. It is an analog of L-arginine that reduces the synthesis
of NO and increases superoxide from inhibition of NOS. A
previous study showed that asthmatic children had higher values
of ADMA than healthy ones with no difference with ICS
treatment (27).
The oxidation of the phospholipid membrane and
polyunsaturated fatty acid produces aldehydes and lipid
hydroperoxides. One study showed high levels of glutathione
in the EBC of asthmatic children with exacerbation and after
5 days of prednisolone therapy, the malondialdehyde level
dropped, while glutathione rose (28). Malondialdehyde levels
also correlate with air pollution, lung function and inflammatory
markers. These results suggest that during exacerbations there is
an imbalance between oxidative and antioxidant agents in the
airways.
H2O2 is released from cells in the airways as superoxide
anions, an unstable and reactive particle. In the respiratory
system, H2O2 can be released from both inflammatory cells—
including neutrophils, macrophages, eosinophils—and epithelial
cells. In non-asthmatic, non-smoking children, the normal value
of this molecule is 0.09 µmol (19). H2O2 was higher in
asthmatic children during exacerbations and decreased after ICS
treatment, supporting the hypothesis that H2O2 is a marker of
airways inflammation (29, 30). However, other studies failed to
demonstrate its ability to predict exacerbations (31, 32).
8-isoprostane, a suitable marker of oxidative stress, is a
product of arachidonic acid (33). Children and adults with
severe asthma or asthma exacerbation have high levels of this
8-isoprostane (34). The concentrations of 8-isoprostane failed
to show any correlation with lung function, FeNO, ICS or
leukotriene receptor antagonist therapy (35, 36).
Eicosanoids are another group of markers derived from
arachidonic acid that play a role in asthmatic inflammation. The
presence of thesemarkers in EBC is confirmed by specific enzyme
immunoassay and radioimmunoassays (37).
Asthmatic children have high levels of leukotriene B4
(LTB4), cysteinyl leukotrienes (LTC4, LTD4, and LTE4) in
EBC (36, 37). The role of cysteinyl leukotrienes (CysLT) in
response to ICS therapy is under debate (38–40). Some authors
showed a significant reduction of CysLT after a course of oral
corticosteroids and after 6 months of ICS therapy, whereas others
did not confirm this result. A significant reduction of CysLTs has
been reported after montelukast therapy (41).
Several other markers of inflammation and oxidative stress,
such as cytokines and adenosine, have been investigated.
Asthmatic children showed high Th2 cytokines and low Th1
cytokines in EBC (42, 43). Moreover, children with asthma had a
high IL-4/INFγ ratio related to Th2 inflammation (43). IL-4 was
high in asthmatic and atopic children as a predictor of asthma
condition, whereas IL-5 could predict exacerbations (32).
FRACTIONAL EXHALED NITRIC OXIDE
(FENO)
Nitric oxide in airways is mainly produced by two enzymes:
constitutive nitric oxide synthase (cNOS), that produces low
quantities of NO, and epithelial inducible NOS (iNOS) that
is induced by various inflammatory cytokines (44). FeNO is a
marker of eosinophilic airway inflammation, able to evaluate
the level of inflammation and the response of anti-inflammatory
therapy (45).
FeNO is a noninvasive, repeatable and reproducible method
(46) applicable in the pediatric practice. The gold standard
technique for cooperative children is the single breath on-line
method (47) but also other techniques have been proposed for
uncooperative children or in sedated infants (47). Nevertheless,
at present, no clear evidence is available regarding the potential
clinical application of FeNO measurements in uncooperative
children. In this age group, themethod deserves additional efforts
to standardization because it its potential application to predict
asthma (33).
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FeNO levels can be influenced by different factors such as
patient’s age, height, gender, and race, nasal contamination,
exhalation flow ambient and air pollution (48). The execution of
spirometry or exercise before the measurement, diet or exposure
to smoke also need to be considered (48).
The standardization of techniques permits to collect
comparable data from different centers in healthy children
and subjects with diseases. For this purpose, the first
document on FeNO evaluation in children was published
in 2002 (47), subsequently revised by ATS/ERS in 2005
(48).
Several studies demonstrated that FeNO correlates with
airway hyperresponsiveness, IgE serum levels, bronchodilator
response, skin prick tests, asthma symptoms, and lung function
(49, 50).
Airway inflammation in allergic asthma results from
the activation of Th2-mediated pro-inflammatory cytokine
mechanism involving IL-4, IL-5, and IL-13. This mechanism
causes the expression of epithelial inducible NO synthase up-
regulated via STAT-6, a process which is corticosteroid sensitive
(51, 52).
Furthermore, other studies showed that FeNO levels are
correlated with serum eosinophilic cation protein, eosinophils in
induced sputum, blood eosinophilia, eosinophil infiltration of the
airways, and IgE levels in atopic patients (52). High FeNO values
characterize Th2-mediated airway inflammation, eosinophilia,
and responsiveness to ICS (52).
FeNO is helpful during evaluation of the patients
characterizing asthma of the eosinophilic phenotype and
predicting asthma exacerbation. In children less than 5-year-old
with recurrent coughing and wheezing, increased FeNO levels
can predict physician diagnosed asthma at school age (53).
Furthermore, increased FeNO levels at the age of 4 years, predict
higher risk for wheezing, asthma and need of ICS by school age
(54).
The ATS guidelines recommend the use of FeNO for
monitoring airway inflammation and for addressing the choice of
anti-inflammatory treatment (52, 55, 56). It has been extensively
proved a rapid decrease of FeNO values when ICS treatment
is started, with a dose-dependent mechanism and a sudden
rise when ICS therapy is withdrawn (57). This trend may
be helpful in monitoring patient adherence to the therapy
(46).
High FeNO values are not always linked to eosinophilic
asthma but also to allergic rhinitis, eosinophilic bronchitis and
allergen or viral exposure and a correct interpretation is stressed
in the ATS/ERS document (55).
In patient treated with omalizumab, FeNO values, blood
eosinophils and BMI can predict the response to the therapy (58).
Authors, for a long time, have been very cautious to support
the use of FeNO as coadjutant to standard symptom-based
management (59, 60).
However, in recent Cochrane review it has been showed that
FeNO guided treatment in asthmatic children was associated
with a significant reduction in exacerbation as compared with
guideline-based treatment (61). On these bases, the most recent
GINA document in 2018 included FeNO guided treatment
as a proposed for tailoring treatment to be considered in
children (1).
Therefore, FeNO can be regarded a useful method to
categorize patients with eosinophilic and Th2-mediated asthma
evaluating the response to ICS therapy, predicting exacerbations
and the compliance to the therapy.
EXHALED BREATH VOLATILE ORGANIC
COMPOUNDS (VOCS)
Exhaled breath volatile organic compounds (VOCs) are analyzed
by breathomics science and they represent a noninvasive tool to
evaluate the lung inflammation. VOCs have a metabolic origin
from larger molecules. Airway VOCs originate not only from the
upper and lower airways but also from a capillary bed near the
alveoli (62). Their concentration in exhaled breath is influenced
by blood gas coefficient, cardiac output and alveolar minute
volume.
The methodological approach to collect VOCs from exhaled
breath requires attention to exclude organic compounds from the
ambient air, type of sampling (total vs. alveolar breath), type of
collecting materials and other confounding factors (62).
In particular, the collection of airway VOCs needs an
inhalation filter to exclude ambient VOCs. The patient is asked
to breath into a system which can collect online samples directly
via inert tubes into an analyzer or off-line by collecting exhaled
air into bags, tubes or syringes. These devices are made of inert
materials such as Tedlar bags (63).
Gas chromatography-mass spectrometry (GC-MS) and flame
ionization detection (GC-FID) are the most widely used
techniques to analyze the samples after collection. Thesemethods
can differentiate and quantify VOCs at low concentrations, but
they require both qualified technicians and expensive technology
(33).
A new non-selective approach to analyze VOCs in exhaled
breath is metabolomic profiling that identify and quantify all
metabolites in a biological sample without a priori hypothesis.
Metabolomic profiles describe the interaction among
environmental exposure, medication, nutrition, and toxic
substances, genetic expression andmicroorganisms (33, 62). This
method is an interesting approach to patient characterization
and personalized medication (33). This approach simultaneously
evaluates many metabolites in a sample and generates a profile
capable of discriminating between different groups of individuals
characterizing the biochemical processes underway in each
biological system.
More recently sensor-based device such as the electronic nose,
colorimetric sensor array, and gold nanoparticle sensors have
been proposed. They adopt specific sensors with optical, chemical
or electronic properties that analyze VOCs in the EB (62).
Recently, some studies have demonstrated the clinical application
of these instruments in respiratory disease (64, 65). VOCs in
the EB discriminate between asthma and healthy and between
atopic and non-atopic children (64, 65). VOCs profile in exhaled
breath was able to discriminate healthy, transient wheezing and
asthmatic children starting from the age of 2-3-year-old (66). In
Frontiers in Pediatrics | www.frontiersin.org 4 July 2018 | Volume 6 | Article 196
Tenero et al. Biomarkers in Airways Inflammation
the pediatric field, VOCs can also predict asthma exacerbations
(67, 68).
Nevertheless, further studies are necessary to evaluate the
clinical utility of VOCs in evaluating asthma severity and
monitoring asthma symptoms and response to ICS therapy.
CONCLUSIONS
Noninvasive techniques to collect and analyze airways
inflammatory biomarkers are helpful in evaluating the airway
pathophysiology of asthmatic children.
In clinical practice, FeNO evaluation has been suggested as
the only valid and non-invasive technique to test for underlined
eosinophilic inflammation, but it would need to be adopted in
combination with other useful markers.
The standardization of the new techniques to collect
biomarkers in EB and EBC remains problematic. Low
reproducibility of exhaled biomarkers and the lack of
standardization of the methods of pre-collection, collection,
post-collection of the samples, along with the correct
interpretation of the results, represent critical issues in clinical
practice.
The identification and utilization of ideal and defined
biomarkers in asthmatic children remains debated. The reasons
for this are the biological aspects of each prospective biomarker,
the disease pathobiology, and methods and invasiveness
of sample collection. Therefore, the development of novel
biomarker with more sensitivity and specificity may lead to
prompt diagnosis of severe asthma in future.
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